Power3 Medical Products, Inc. (OTC:PWRM)
PWRM, a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, announced earlier this month that it delivered four poster presentations at the 2010 International Conference on Alzheimer's Disease (NASDAQ:ICAD) in Honolulu, Hawaii. These presentations discussed NuroPro, PWRM's diagnostic test, and focused on PWRM's Alzheimer's disease blood serum biomarkers, test and clinical validation trials.
"In preparation for commercialization, our objective at this meeting was to show how Power3's protein biomarkers and blood tests provide superior solutions for diagnosis and drug response to improve the treatment of Alzheimer's disease," said Dr. Ira L. Goldknopf, PWRM's President and Chief Scientific Officer. "It was gratifying to receive substantial attention to our posters from representatives of major pharma and clinical research institutions from around the world. They expressed surprise and enthusiasm for our findings, especially those relating to the methods by which Power3's protein biomarkers indicate how patients respond to treatment with the three major anti-dementia drugs."
"We are pleased that our blood tests specifically diagnose Alzheimer's in patients, both pre- and post-treatment," said Helen R. Park, MS, Chief Executive Officer of PWRM, "and that our scientific collaborators, Dr. Marwan Sabbagh, Medical and Scientific Director of the Banner Sun Health Medical Research Institute, and Dr. Lourdes R. Bosquez, President of the Woodlands Behavioral Institute, Inc., presented along with us at the meeting in Hawaii."
"We are within striking distance of realizing an Alzheimer's clinical diagnostic tool which I hope will lead to a greater understanding of the disease and buoy the pace of future therapeutic interventions," added Marwan Sabbagh MD, Medical and Scientific Director of Banner Sun Health Medical Research Institute.
PWRM has filed several patent applications for its NuroPro technology that are currently pending. PWRM also has a world-wide exclusive license from the Baylor College of Medicine in Houston, Texas. To date, PWRM has given 9 presentations on NuroPro at international scientific meetings in the United States, Europe and China, and has published 6 articles in peer-reviewed scientific journals on the subject. PWRM intends to publish these latest findings as well.
PWRM, a bio-technology company, engages in the development and marketing of diagnostic tests in the fields of cancer, and neurodegenerative and neuromuscular diseases in the United States. PWRM's products include BC-SeraPro, a proteomic blood serum test for the early detection of breast cancer; and NuroPro, a serum test for the detection of neurodegenerative diseases, such as amyotrophic lateral sclerosis, Alzheimer's disease, and Parkinson's disease. PWRM's products analyze proteins and their mutations to assess an individual's risk for developing disease later in life or a patient's likelihood of responding to a particular drug; assess a patient's risk of disease progression and disease recurrence; and measure a patient's exposure to drug therapy. PWRM was formerly known as Surgical Safety Products, Inc. and changed its name to Power3 Medical Products, Inc. in September 2003. PWRM was founded in 1992 and is based in The Woodlands, Texas.
To learn more about PWRM visit: http://www.Power3Medical.com
Fresenius Medical Care AG & Co. KGaA (NYSE:FMS)
FMS, the world's largest provider of dialysis products and services, today announced that it has signed an agreement to acquire Gambro's worldwide peritoneal dialysis (PD) business. Gambro has decided to prioritize its investments in the hemodialysis field. FMS is taking advantage of this opportunity to expand its activities in the homecare market, especially in Europe and Asia-Pacific.
FMS, a kidney dialysis company, offers dialysis treatment services through its clinics. As of December 31, 2009, FMS provided dialysis treatment to 195,651 patients in 2,553 clinics worldwide located in approximately 35 countries. FMS also performs clinical laboratory testing services, including blood, urine, and other bodily fluid testing services, as well as provides inpatient dialysis and other services under contract to hospitals. FMS was founded in 1996 and is headquartered in Bad Homburg, Germany.
To learn more about FMS visit: http://www.fmc-ag.com
Fresh Del Monte Produce Inc. (NYSE:FDP)
FDP recently reported financial results for the second quarter ended July 2, 2010. Excluding asset impairment and other charges, net, FDP reported earnings per diluted share of $0.85 for the second quarter of 2010, compared with earnings per diluted share of $1.11 in the second quarter of 2009. Asset impairment and other charges, net totaled $31.5 million, or $0.51 per diluted share, for the second quarter of 2010, primarily as a result of exit activities in South Africa and Brazil, and flood damage to FDP's Guatemala banana production operation. Results for the second quarter of 2009 exclude asset impairment and other charges, net totaling $18.2 million, or $0.29 per diluted share.
FDP, together with its subsidiaries, produces, transports, sources, markets, and distributes fresh and fresh-cut fruit and vegetables worldwide. FDP was founded in 1886 and is based in George Town, Cayman Islands.
To learn more about FDP visit: http://www.freshdelmonte.com
Friedman Industries, Incorporated (Amex:FRD)
The Board of Directors of FRD, a Texas-based company engaged in pipe manufacturing, steel processing and steel and pipe distribution, declared on September 2, 2010, a quarterly cash dividend of $0.08 per share on the Common Stock of FRD. FRD will pay the cash dividend on November 19, 2010, to shareholders of record at the close of business on October 22, 2010.
FRD, together with its subsidiaries, engages in steel processing, pipe manufacturing and processing, and steel and pipe distribution in the United States. FRD was founded in 1965 and is based in Houston, Texas.
To learn more about FRD visit: http://www.friedmanindustries.com
Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwefinance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE) has previously received five hundred thousand shares as compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (OTC:PWRM). Recently, Crown Equity Holdings Inc. had received an additional amount of 2,000,000 shares of free trading stock for 60 days of media advertisement, web design and maintenance for Power 3 Medical Products Inc. (OTC:PWRM). Each advertising commitment has now expired.
Disclosure: No positions